Статья

The Cancer Genome Atlas Pan-Cancer analysis project

John N. WeinsteinDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USAEric A CollissonDepartment of Medicine, University of California, San Francisco, San Francisco, California, USAGordon B. MillsDepartment of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USAKenna ShawThe Cancer Genome Atlas Program Office, Center for Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USABrad OzenbergerNational Human Genome Research Institute, US National Institutes of Health, Bethesda, Maryland, USAKyle EllrottCenter for Biomolecular Science and Engineering, University of California, Santa Cruz, Santa Cruz, California, USAIlya ShmulevichInstitute for Systems Biology, Seattle, Washington, USAChris SanderComputational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, New York, USAJoshua M. StuartCenter for Biomolecular Science and Engineering, University of California, Santa Cruz, Santa Cruz, California, USA

2013en

ABI

Аннотация

Current clinical practice is organized according to tissue or organ of origin of tumors. Now, The Cancer Genome Atlas (TCGA) Research Network has started to identify genomic and other molecular commonalities among a dozen different types of cancer. Emerging similarities and contrasts will form the basis for targeted therapies of the future and for repurposing existing therapies by molecular rather than histological similarities of the diseases. The Cancer Genome Atlas (TCGA) Research Network has profiled and analyzed large numbers of human tumors to discover molecular aberrations at the DNA, RNA, protein and epigenetic levels. The resulting rich data provide a major opportunity to develop an integrated picture of commonalities, differences and emergent themes across tumor lineages. The Pan-Cancer initiative compares the first 12 tumor types profiled by TCGA. Analysis of the molecular aberrations and their functional roles across tumor types will teach us how to extend therapies effective in one cancer type to others with a similar genomic profile.

Перевод пока недоступен

Идентификаторы

DOI: 10.1038/ng.2764

Цитирования и источники

Цитирований: 4Использованных источников: 0

Показатели — AkademScholar